Pharmacogenomics Overview

Principles

Definition

Pharmacogenomics is a field of research that investigates the influence of genetic variation on drug response. This discipline seeks to optimize therapeutic outcomes and minimize adverse drug reactions by using an individual's genetic profile to predict differences in drug metabolism, transport, and target interaction, thereby advancing personalized medicine.

Ontological type

Clinical Implementation

Core Concepts

Key Technologies

Key developments

Key Figures

Mechanistic Foundations era

Timothy M. Willson [1] was a prominent figure during the Mechanistic Foundations era, with affiliations to University of Pennsylvania [2] and University of California, San Diego [3]. His key contribution in this era centers on the human orphan nuclear receptor PXR and its regulation of CYP3A4 gene expression and drug interactions, as documented in the paper The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions [4]. This mechanistic work provided a foundational link between nuclear receptor biology and drug metabolism, shaping early pharmacogenetic hypotheses and risk-stratification approaches in the era. Willson [1]'s contributions thus anchored the era's approach to translating mechanistic pharmacology into actionable pharmacogenetic inquiry.

Genotype-Guided Translation era

P. Andrew Futreal [1] is associated with the Institute of Cancer Research [3] and Stanford University [4] during the Genotype-Guided Translation era. His key contribution is the Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells [6], which was pivotal for translating genomic associations into genotype-guided therapy during this era. Michael R. Stratton [2] is associated with the Institute of Cancer Research [3] and Radboud University Nijmegen [5] during the era. Stratton's contributions through the Genomics of Drug Sensitivity in Cancer (GDSC) [6] helped catalyze consensus guideline development, testing workflows, and informatics platforms essential for implementing genotype-guided therapy.

Implementation and Integration era

Munir Pirmohamed [1] is a leading pharmacogenomics scholar active across major centers such as Harvard University [3] and University College London [4] during the Implementation and Integration era (2017–2023). Munir Pirmohamed [1] contributed a pivotal landmark through the CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update [5], which standardized genotype-informed dosing and stimulated guideline development and real-world adoption. Mia Wadelius [2] is associated with Harvard University [3] and University College London [4] in this era, illustrating cross-institutional collaboration in pharmacogenomics implementation. Mia Wadelius [2] helped advance genotype-guided prescribing via the CPIC guideline paper [5], reinforcing how standardized guidance supports decision support, payer alignment, and wide-scale integration into clinical care.